ZA201907372B - Methods and compositions for treating inflammatory gastrointestinal disorders - Google Patents

Methods and compositions for treating inflammatory gastrointestinal disorders

Info

Publication number
ZA201907372B
ZA201907372B ZA2019/07372A ZA201907372A ZA201907372B ZA 201907372 B ZA201907372 B ZA 201907372B ZA 2019/07372 A ZA2019/07372 A ZA 2019/07372A ZA 201907372 A ZA201907372 A ZA 201907372A ZA 201907372 B ZA201907372 B ZA 201907372B
Authority
ZA
South Africa
Prior art keywords
eosinophilic
compositions
methods
egid
ibd
Prior art date
Application number
ZA2019/07372A
Other languages
English (en)
Inventor
Robert Bebbington Christopher
Andrew Youngblood Bradford
Tomasevic Nenad
C Brock Emily
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of ZA201907372B publication Critical patent/ZA201907372B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • Theoretical Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2019/07372A 2017-05-05 2019-11-06 Methods and compositions for treating inflammatory gastrointestinal disorders ZA201907372B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502480P 2017-05-05 2017-05-05
US201762572337P 2017-10-13 2017-10-13
PCT/US2018/031231 WO2018204871A1 (en) 2017-05-05 2018-05-04 Methods and compositions for treating inflammatory gastrointestinal disorders

Publications (1)

Publication Number Publication Date
ZA201907372B true ZA201907372B (en) 2024-04-24

Family

ID=64016746

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07372A ZA201907372B (en) 2017-05-05 2019-11-06 Methods and compositions for treating inflammatory gastrointestinal disorders

Country Status (13)

Country Link
US (1) US20200270344A1 (enExample)
EP (1) EP3618872A4 (enExample)
JP (2) JP7346304B2 (enExample)
KR (1) KR20200015511A (enExample)
CN (1) CN111246880A (enExample)
AU (1) AU2018263937A1 (enExample)
BR (1) BR112019022957A2 (enExample)
CA (1) CA3062430A1 (enExample)
IL (1) IL270304B2 (enExample)
MX (1) MX2019013136A (enExample)
SG (2) SG10202112259VA (enExample)
WO (1) WO2018204871A1 (enExample)
ZA (1) ZA201907372B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
HK1254432A1 (zh) 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
CA3087063A1 (en) 2017-12-29 2019-07-04 Cornell University Gene therapy for eosinophilic disorders
BR112021015009A2 (pt) * 2019-02-15 2021-10-05 Allakos Inc. Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
EP4469601A1 (en) * 2022-01-24 2024-12-04 Children's Hospital Medical Center Methods of treating eosinophilic colitis
US20240225536A9 (en) * 2022-10-21 2024-07-11 Case Western Reserve University Radiomics signatures for pathologic characterization of strictures on mr and ct enterography
IL323497A (en) * 2023-03-27 2025-11-01 Regeneron Pharma Methods for treating eosinophilic gastroenteritis by administering an IL-4R antagonist
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745421B2 (en) * 2004-05-25 2010-06-29 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
AU2008255352B2 (en) * 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
EP2465873A1 (en) * 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
AU2012272559C1 (en) * 2011-06-23 2017-04-20 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
US9260756B2 (en) * 2012-02-24 2016-02-16 Children's Hospital Medical Center Esophageal microRNA expression profiles in eosinophilic esophagitis
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20210125114A (ko) * 2013-12-09 2021-10-15 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
JP6825909B2 (ja) * 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
HK1254432A1 (zh) * 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
BR112019022912A2 (pt) * 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
GB201820174D0 (en) * 2018-12-11 2019-01-23 Nordic Semiconductor Asa Radio communication
BR112021015009A2 (pt) * 2019-02-15 2021-10-05 Allakos Inc. Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
JP2022535400A (ja) * 2019-06-07 2022-08-08 エピセリオン サイエンス バイオテック，エセ．エレ． 好酸球性消化管疾患の処置のためのイルソグラジン
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
JP2023511279A (ja) * 2020-01-13 2023-03-17 フルーエント バイオサイエンシーズ インコーポレイテッド 単一細胞シーケンシング
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
US20240254441A1 (en) * 2021-06-04 2024-08-01 Kirin Holdings Kabushiki Kaisha Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
KR20250007535A (ko) * 2022-04-22 2025-01-14 인히브릭스 바이오사이언스, 인크. Siglec-8 결합 단백질 및 그 용도

Also Published As

Publication number Publication date
IL270304B1 (en) 2024-03-01
AU2018263937A1 (en) 2019-12-05
IL270304A (en) 2019-12-31
JP7346304B2 (ja) 2023-09-19
CN111246880A (zh) 2020-06-05
IL270304B2 (en) 2024-07-01
US20200270344A1 (en) 2020-08-27
CA3062430A1 (en) 2018-11-08
KR20200015511A (ko) 2020-02-12
SG10202112259VA (en) 2021-12-30
SG11201910206QA (en) 2019-11-28
JP2020518645A (ja) 2020-06-25
EP3618872A1 (en) 2020-03-11
BR112019022957A2 (pt) 2020-05-19
MX2019013136A (es) 2020-07-14
WO2018204871A1 (en) 2018-11-08
EP3618872A4 (en) 2021-06-30
JP2023099232A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
MX2019013136A (es) Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios.
MX2022010224A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MX2024010240A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MY178160A (en) Anti-egfrviii antibodies and uses thereof
HK1250238A1 (zh) 抗angptl8抗体及其用途
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2015013163A (es) Complejos multiespecificos multivalente y monovalentes y sus usos.
PH12020550908A1 (en) Anti-cxcr5 antibodies and compositions and uses thereof
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
EA201592203A1 (ru) Способы лечения таупатии
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
HK1259083A1 (zh) 用於治疗系统性肥大细胞增多症的方法和组合物